Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)
RBC Capital Sticks to Their Buy Rating for Applied Therapeutics (APLT)
Applied Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Applied Therapeutics (APLT) and Vincerx Pharma Inc (VINC)
Applied Therapeutics Analyst Ratings
RBC Capital Initiates Coverage On Applied Therapeutics With Outperform Rating, Announces Price Target of $12
RBC Initiates Applied Therapeutics at Outperform, Speculative Risk With $12 Price Target, Sees Lead Drug Govorestat 'Well-Positioned for Success'
Applied Therapeutics Analyst Ratings
UBS Maintains Buy on Applied Therapeutics, Raises Price Target to $13
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)
Optimistic Buy Rating for Applied Therapeutics Amid Favorable Drug Approval Prospects and Strong Financial Position
Buy Rating Affirmed for Applied Therapeutics as FDA Prioritizes Govorestat, Signaling Strong Market Prospects
Applied Therapeutics Analyst Ratings
Applied Therapeutics Analyst Ratings
Optimistic Buy Rating for Applied Therapeutics: Strategic Regulatory Moves and Favorable Outlook for Govorestat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Applied Therapeutics (APLT) and Align Tech (ALGN)
Applied Therapeutics (APLT) Receives a Buy From Robert W. Baird
Robert W. Baird Remains a Buy on Applied Therapeutics (APLT)
Baird Adjusts Applied Therapeutics Price Target to $14 From $18, Maintains Outperform Rating